- Home
- PROV vs RGLS Comparison
PROV vs RGLS Comparison
Compare PROV & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROV
- RGLS
- Stock Information
- Founded
- PROV 1956
- RGLS 2007
- Country
- PROV United States
- RGLS United States
- Employees
- PROV N/A
- RGLS N/A
- Industry
- PROV Savings Institutions
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- PROV Finance
- RGLS Health Care
- Exchange
- PROV Nasdaq
- RGLS Nasdaq
- Market Cap
- PROV 106.8M
- RGLS 102.1M
- IPO Year
- PROV 1996
- RGLS 2012
- Fundamental
- Price
- PROV $15.72
- RGLS $1.47
- Analyst Decision
- PROV Hold
- RGLS Strong Buy
- Analyst Count
- PROV 1
- RGLS 6
- Target Price
- PROV $16.00
- RGLS $10.33
- AVG Volume (30 Days)
- PROV 7.6K
- RGLS 500.1K
- Earning Date
- PROV 10-28-2024
- RGLS 11-07-2024
- Dividend Yield
- PROV 3.53%
- RGLS N/A
- EPS Growth
- PROV N/A
- RGLS N/A
- EPS
- PROV 1.09
- RGLS N/A
- Revenue
- PROV $39,794,000.00
- RGLS N/A
- Revenue This Year
- PROV N/A
- RGLS N/A
- Revenue Next Year
- PROV $11.75
- RGLS N/A
- P/E Ratio
- PROV $14.48
- RGLS N/A
- Revenue Growth
- PROV N/A
- RGLS N/A
- 52 Week Low
- PROV $11.10
- RGLS $1.08
- 52 Week High
- PROV $16.24
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- PROV 55.82
- RGLS 48.95
- Support Level
- PROV $15.56
- RGLS $1.30
- Resistance Level
- PROV $15.90
- RGLS $1.65
- Average True Range (ATR)
- PROV 0.33
- RGLS 0.10
- MACD
- PROV -0.04
- RGLS -0.00
- Stochastic Oscillator
- PROV 50.00
- RGLS 48.57
About PROV Provident Financial Holdings Inc.
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. Through the bank, it is engaged in providing community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The company's business segment is Bank. The Bank's activities include attracting deposits, offering banking services, and originating and purchasing single-family, multi-family, commercial real estate, construction, and other mortgage loans and, to a lesser extent, commercial business and consumer loans held for investment.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.